It's all changing at Zeiss
Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with new CEO, Dr Michael Kaschke, about the challenges that he faces in an ever-evolving market.
Recent acquisitions, division restructuring, and management changes prove that Carl Zeiss Meditec is very much committed to change. Ophthalmology Times Europe spoke with new CEO, Dr Michael Kaschke, about the challenges that he faces in an ever-evolving market.
Connectivity of devices is a big focus for Zeiss. According to Dr Kaschke, doctors want simplicity and, in order to give them this, Zeiss must commit to providing seamless workflow solutions.
As part of this enhanced product offering, one cannot forget last year’s acquisition of Acri.Tec, which well and truly catapulted the company into the IOL market.
Although it believes it now has the best lenses on the market carrying its name, new lens launches continue to be announced by Zeiss. In fact, three new lenses will soon be added to its portfolio. Specifically, the three yellow IOLs: Acri.Lyc 44YLC, Acri.Smart 46YLC, and Acri.Lyc 47YLC, will be available in Europe by the end of the year.
To read the full interview, please click here.
To read OTE's full news coverage of the XXVI congress of the European Society of Cataract & Refractive Surgery, please click here.
Newsletter
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.
